Cargando…
Amyotrophic Lateral Sclerosis (ALS) prediction model derived from plasma and CSF biomarkers
Amyotrophic Lateral Sclerosis (ALS) is a degenerative disorder of motor neurons which leads to complete loss of movement in patients. The only FDA approved drug Riluzole provides only symptomatic relief to patients. Early Diagnosis of the disease warrants the importance of diagnostic and prognostic...
Autores principales: | Khosla, Radhika, Rain, Manjari, Sharma, Suresh, Anand, Akshay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894922/ https://www.ncbi.nlm.nih.gov/pubmed/33606761 http://dx.doi.org/10.1371/journal.pone.0247025 |
Ejemplares similares
-
Association of Plasma Biomarkers for Angiogenesis and Proteinopathy in Indian Amyotrophic Lateral Sclerosis Patients
por: Modgil, Shweta, et al.
Publicado: (2020) -
Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in Amyotrophic Lateral Sclerosis (ALS) patients
por: Gupta, Pawan K, et al.
Publicado: (2011) -
Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients
por: Gupta, Pawan K, et al.
Publicado: (2011) -
Can Cheiromancy Predict Mean Survival or Fatality of a Patient with Amyotrophic Lateral Sclerosis?
por: Anand, Akshay, et al.
Publicado: (2020) -
UCHL1 from serum and CSF is a candidate biomarker for amyotrophic lateral sclerosis
por: Li, Ruibing, et al.
Publicado: (2020)